Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

Rhea-AI Summary

Applied Therapeutics, Inc. (Nasdaq: APLT) announced its participation in two investor conferences in March 2021. The first is the Cowen 41st Annual Health Care Conference on March 2, 2021, from 9:10 to 9:40 a.m. ET. The second is the Barclays Global Healthcare Conference scheduled for March 9, 2021, from 4:45 to 5:10 p.m. ET. The webcasts will be available on their website's Investor Relations section, with a replay option post-event. Applied Therapeutics develops novel drug candidates targeting high unmet medical needs, including treatments for rare diseases.

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced today that it will present at two upcoming investor conferences in March:

Cowen 41^st Annual Health Care Conference
Date: Tuesday, March 2, 2021
Time: 9:10 – 9:40 a.m. ET

Barclays Global Healthcare Conference
Date: Tuesday, March 9, 2021
Time: 4:45 – 5:10 p.m. ET

Webcast information for these events will be accessible on the Events page under the Investor Relations section of the Applied Therapeutics website at www.appliedtherapeutics.com. A replay will also be available following the webcast.

About Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, AT-007, is a novel central nervous system penetrant aldose reductase inhibitor (ARI) for the treatment of Galactosemia, a rare pediatric metabolic disease. The Company initiated a pivotal Phase 1/2 clinical trial in June 2019, read out positive top-line biomarker data in adult Galactosemia patients in January 2020 and announced full data from the trial in April 2020. The Company is also developing AT-001, a novel potent ARI that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The Company initiated a Phase 3 registrational study in DbCM in September 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, as well as novel dual PI3k inhibitors in preclinical development for orphan oncology indications.

Investors:
Maeve Conneighton
(212) 600-1902 or
appliedtherapeutics@argotpartners.com

Media:
Gleb Sagitov
media@appliedtherapeutics.com

 

FAQ

What investor conferences will APLT participate in March 2021?

Applied Therapeutics will participate in the Cowen 41st Annual Health Care Conference on March 2 and the Barclays Global Healthcare Conference on March 9, 2021.

What is the date and time of APLT's presentation at the Cowen Conference?

The Cowen 41st Annual Health Care Conference presentation will take place on March 2, 2021, from 9:10 to 9:40 a.m. ET.

When will APLT present at the Barclays Global Healthcare Conference?

Applied Therapeutics will present at the Barclays Global Healthcare Conference on March 9, 2021, from 4:45 to 5:10 p.m. ET.

Where can I find the webcast for APLT's investor presentations?

Webcast information for Applied Therapeutics' presentations will be available on their website under the Investor Relations section.

What is APLT's lead drug candidate and its purpose?

Applied Therapeutics' lead drug candidate, AT-007, is developed for treating Galactosemia, a rare pediatric metabolic disease.